Sanofi A/S — Regnskab

CVR 19064301

Seneste regnskabsperiode

  • 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • 442343000 • 100902000 • 8361000 • 5043000 • 232819000 • 58663000 • 78000

Regnskabshistorik

  • 2024 • 2024-01-01 • 2024-12-31 • entity • DKK • 452617000 • 107095000 • 9565000 • 6217000 • 192036000 • 53620000 • 81
  • 2023 • 2023-01-01 • 2023-12-31 • entity • DKK • 527584000 • 102537000 • 6985000 • 3697000 • 166242000 • 47403000 • 83
  • 2022 • 2022-01-01 • 2022-12-31 • entity • DKK • 530879000 • 114996000 • 20610000 • 15919000 • 179873000 • 43706000 • 85
  • 2021 • 2021-01-01 • 2021-12-31 • entity • DKK • 591149000 • 135675000 • 34437000 • 21982000 • 223188000 • 69317000 • 86
  • 2020 • 2020-01-01 • 2020-12-31 • entity • DKK • 563450000 • 204343000 • 86900000 • 67215000 • 225760000 • 77175000 • 100
  • 2019 • 2019-01-01 • 2019-12-31 • entity • DKK • 485721000 • 114941000 • 10966000 • 7223000 • 164663000 • 23343000 • 99
  • 2018 • 2018-01-01 • 2018-12-31 • entity • DKK • 433862252 • 98672531 • -2108318 • -3056222 • 176844927 • 16120199 • 97
  • 2017 • 2017-01-01 • 2017-12-31 • entity • DKK • 421219650 • 113324356 • 16883550 • 11629981 • 160424022 • 19176421 • 95
  • 2016 • 2016-01-01 • 2016-12-31 • entity • DKK • 435538000 • 7689000 • 32546000 • 78

Højdepunkter fra årsrapporten

  • primary activities • Revenue for 2025 amounted to DKK 442,343 thousand, representing a decline of approximately 2.3% compared to DKK 452,617 thousand in 2024. This development was broadly in line with management's estimated outlook for the year. Net profit for 2025 was DKK 5,043 thousand, compared to DKK 6,217 thousand in 2024. While profitability remained positive, the result is at the lower end of the estimated profit range of DKK 5,000–15,000 thousand for the year, primarily reflecting continued pressure on gross margins and increased net financial costs. Notably, total assets grew significantly by 21.24% to DKK 232,819 thousand, and equity increased to DKK 58,663 thousand, reflecting a strengthened balance sheet position. Return on equity decreased to 8.98% (2024: 12.31%), as the growth in the equity base outpaced the increase in net profit, resulting in a lower return ratio despite the positive profit result. The equity ratio stood at 25.20% (2024: 27.92%), reflecting the proportionally larger growth in total assets relative to equity. • entity
  • primary activities • Revenue for 2025 amounted to DKK 442,343 thousand, representing a decline of approximately 2.3% compared to DKK 452,617 thousand in 2024. This development was broadly in line with management's estimated outlook for the year.Net profit for 2025 was DKK 5,043 thousand, compared to DKK 6,217 thousand in 2024. While profitability remained positive, the result is at the lower end of the estimated profit range of DKK 5,000–15,000 thousand for the year, primarily reflecting continued pressure on gross margins and increased net financial costs.Notably, total assets grew significantly by 21.24% to DKK 232,819 thousand, and equity increased to DKK 58,663 thousand, reflecting a strengthened balance sheet position. Return on equity decreased to 8.98% (2024: 12.31%), as the growth in the equity base outpaced the increase in net profit, resulting in a lower return ratio despite the positive profit result. The equity ratio stood at 25.20% (2024: 27.92%), reflecting the proportionally larger growth in total assets relative to equity. • entity
  • contingent liabilities • The Danish tax authorities are conducting an audit of the transfer pricing policies of the company for the years 2018 - 2020. At this stage, the tax authorities are proposing to increase the taxable income of Sanofi. Sanofi’s current position is fully consistent with the global transfer pricing policy and as such Sanofi disagrees with the initial proposition of the Danish Tax Authorities. • entity
  • contingent liabilities • The Danish tax authorities are conducting an audit of the transfer pricing policies of the company for the years 2018 - 2020. At this stage, the tax authorities are proposing to increase the taxable income of Sanofi.Sanofi’s current position is fully consistent with the global transfer pricing policy and as such Sanofi disagrees with the initial proposition of the Danish Tax Authorities. • entity
  • mortgages collateral • The Company has not provided any security or other collateral in assets at 31 December 2025. • entity